Can histone deacetylase inhibitors uncover novel therapeutic agents for inherited retinal dystrophies

DC FieldValueLanguage
dc.contributor.authorSundaramurthi, Husvinee-
dc.contributor.authorRueckert, H.-
dc.contributor.authorMoran, Ailís-
dc.contributor.authorReynolds, Alison-
dc.contributor.authorKennedy, Breandán-
dc.date.accessioned2019-05-08T14:06:55Z-
dc.date.available2019-05-08T14:06:55Z-
dc.date.issued2017-12-13-
dc.identifier.issn1741-1157-
dc.identifier.urihttp://hdl.handle.net/10197/10357-
dc.descriptionBritish Pharmacological Society (BPS) Pharmacology 2017, London, England, 11-13 December 2017en_US
dc.description.abstractInherited retinal dystrophies (iRDs) affect 1 in 3000 people worldwide and effective treatment options are not widely available due to the genetic and clinical heterogeneity. Recently, histone deacetylase inhibitors (HDACi) have gained attention as a potential therapeutic option based on their neuroprotective effects within the retina. However, the benefits of HDACi remains highly controversial, and their downstream mechanism of action are yet to be thoroughly elucidated. Preliminary data from studies conducted has shown that treatment of zebrafish retinal mutant with HDACi, trichostatin A (TSA), could rescue visual capacity and retinal morphology. The current study is designed to address the suitability of HDACi as therapeutic options for iRDs using zebrafish models.en_US
dc.language.isoenen_US
dc.subjectInherited retinal dystrophies (iRDs)en_US
dc.subjectTreatment optionsen_US
dc.subjectHistone deacetylase inhibitors (HDACi)en_US
dc.subjectNeuroprotective effectsen_US
dc.subjectRetinaen_US
dc.subjectVisual capacityen_US
dc.subjectRetinal morphologyen_US
dc.titleCan histone deacetylase inhibitors uncover novel therapeutic agents for inherited retinal dystrophiesen_US
dc.typeConference Publicationen_US
dc.internal.authorcontactotherbrendan.kennedy@ucd.ieen_US
dc.internal.webversionshttps://www.emedevents.com/c/medical-conferences-2017/british-pharmacological-society-bps-pharmacology-2017-
dc.statusPeer revieweden_US
dc.check.date2019-05-22-
dc.neeo.contributorSundaramurthi|Husvinee|aut|-
dc.neeo.contributorRueckert|H.|aut|-
dc.neeo.contributorMoran|Ailís|aut|-
dc.neeo.contributorReynolds|Alison|aut|-
dc.neeo.contributorKennedy|Breandán|aut|-
dc.description.othersponsorshipFighting Blindnessen_US
dc.date.updated2018-09-21T08:07:41Z-
dc.identifier.grantidFB14KEN-
item.fulltextWith Fulltext-
item.grantfulltextopen-
Appears in Collections:Biomolecular and Biomedical Science Research Collection
Files in This Item:
File Description SizeFormat 
1vol18issue1abst172p.pdf54.15 kBAdobe PDFDownload
Show simple item record

Google ScholarTM

Check


This item is available under the Attribution-NonCommercial-NoDerivs 3.0 Ireland. No item may be reproduced for commercial purposes. For other possible restrictions on use please refer to the publisher's URL where this is made available, or to notes contained in the item itself. Other terms may apply.